Cargando…
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
AIMS: Nadroparin is administered to COVID‐19 intensive care unit (ICU) patients as thromboprophylaxis. Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID‐19 ICU patients is unknown. Moreover, optimal dosing regimens achievin...
Autores principales: | Romano, Lorenzo G. R., Hunfeld, Nicole G. M., Kruip, Marieke J. H. A., Endeman, Henrik, Preijers, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878197/ https://www.ncbi.nlm.nih.gov/pubmed/36495312 http://dx.doi.org/10.1111/bcp.15634 |
Ejemplares similares
-
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
por: Jaspers, Tessa C. C., et al.
Publicado: (2022) -
Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
por: Martial, Lisa C., et al.
Publicado: (2017) -
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020) -
Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19
por: Piwowarczyk, Paweł, et al.
Publicado: (2023) -
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
por: Barni, Sandro, et al.
Publicado: (2011)